Biofrontera AG

Corporate Details

ISIN(s):

DE000A409625 (+2 more)

LEI:

391200D6GFSVFGFQTL13

Country:

Germany

Address:

Hemmelrather Weg 201, 51377 Leverkusen

Website:

https://www.biofrontera.com/en/

Sector:

Professional, scientific and technical activities

Industry:

Research and experimental development on natural sciences and engineering

Description

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz;, a topical prescription drug, and medical device BF-RhodoLED; for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz; has been marketed in the EU since 2012 and in the United States since May 2016. Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Luebbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.